Damian Garde

From the corporate jets of Teterboro Airport to the crowded halls of the J.P. Morgan Healthcare Conference, it's a good time to be a pharmaceutical executive.

Sarepta Therapeutics' next crop of medicines for muscular dystrophy appear to be safe and effective in early clinical trials, the company said, a positive though incremental update for a drugmaker rebuilding its business after a tumultuous 2025.

We're here in San Diego, on the ground at AACR — one of the best places to spot early cancer research that will turn out to be important later on.

Dana-Farber study yielded strong results in 20 patients with smoldering multiple myeloma

You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening at the American Association of Cancer Researchers' annual meeting. Sign up here

At AACR, there was talk of Chinese biotech's place in cancer research, oncology’s comms issue, and more.

In the meantime, thanks for joining us. Overcoming resistance and RevMed's next drug?

Trump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.

There's a schism in America's drug business, playing out in punchy direct messages, feisty group chats, and the occasional heated in-person exchange.

This story is republished from STAT , the health and medicine news site that's a partner to the Globe. Sign up for STAT's free Morning Rounds newsletter here